The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy.

Jeong, Tae-Jun; Lee, Hyun-Tae; Gu, Nahyeon; Jang, Yu-Jeong; Choi, Seung-Beom; Park, Ui-Beom; Lee, Sang-Hyung; Heo, Yong-Seok

Jeong, Tae-Jun; Lee, Hyun-Tae; Gu, Nahyeon; Jang, Yu-Jeong; Choi, Seung-Beom; Park, Ui-Beom; Lee, Sang-Hyung; Heo, Yong-Seok.

Afiliação

Jeong TJ; Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea.
Lee HT; Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea.
Gu N; Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea.
Jang YJ; Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea.
Choi SB; Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea.
Park UB; Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea.
Lee SH; Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea.
Heo YS; Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea.

Biomedicines ; 10(12)2022 Dec 06.

Article em En | MEDLINE | ID: mdl-36551910

Palavras-chave

PD-1; antibody; cancer immunotherapy; cemiplimab; crystal structure; dostarlimab; immune checkpoint; nivolumab; pembrolizumab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Biomedicines Ano de publicação: 2022 Tipo de documento: Article País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google